AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
With a market cap of 377.9B, AbbVie(ABBV) trades at $213.90. The stock has a price-to-earnings ratio of 105.43 and currently yields dividends of 3.2%.
On 2026-05-20, AbbVie(ABBV) stock moved within a range of $213.90 to $214.41. With shares now at $213.90, the stock is trading 0.0% above its intraday low and -0.2% below the session's peak.
Trading activity shows a volume of 3.32K, compared to an average daily volume of 5.92M.
The stock's 52-week range extends from a low of $180.25 to a high of $244.81.
The stock's 52-week range extends from a low of $180.25 to a high of $244.81.
ABBV News
Abbvie ((ABBV)) has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock hedge fund-level data and powerful inv...
UCB (UCBJY) announced on Tuesday that its biologic medicine Bimzelx outperformed AbbVie’s (ABBV) immunology therapy Skyrizi in a head-to-head trial for psoriati...
The analyst who called NVIDIA in 2010 just named his top 10 stocks and AbbVie wasn't one of them. Get them here FREE . Income investors are increasingly abando...
Analyst ratings
73%
of 33 ratingsMore ABBV News
Evercore ISI lowered the firm’s price target on AbbVie (ABBV) to $235 from $236 and keeps an Outperform rating on the shares. Unlock hedge fund-level data and...
The market was pleased with the recent earnings report from AbbVie Inc. ( ), despite the profit numbers being soft. Our analysis suggests that investors may hav...
Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Di...
Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Di...
Reports Q1 revenue $6.4M vs. $89M last year. “REGENXBIO (RGNX) enters a transformative year with positive momentum, reaching significant late-stage milestones t...
Advertisement What AbbVie’s Recent Performance Tells You AbbVie (ABBV) has drawn investor attention after a mixed recent run in the stock. The share price is...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.